CAS:1794779-79-5|Chlorpropamide-d4

CAS:1794779-79-5|Chlorpropamide-d4

Catalogue Number:C424802
Chemical Name:Chlorpropamide-d4
Synonyms:4-Chloro-N-[(propylamino)carbonyl]benzenesulfonamide-d4; Adiaben-d4; Asucrol-d4; Catanil-d4; Chlorodiabina-d4; Chloronase-d4; Chloropropamide-d4; Chlorpropamid-d4; Diabaril-d4; Diabechlor-d4; Diabenal-d4; Diabenese-d4; Glisema-d4; Meldian-d4; Melitase-d4; Millinese-d4; N-(4-Chlorophenylsulfonyl)-N’-propylurea-d4; NSC 44634-d4; NSC 626720-d4; P 607-d4; Stabinol-d4; U 9818-d4; N-(p-Chlorobenzenesulfonyl)-N’-propylurea-d4; N-Propyl-N’-(p-chlorobenzenesulfonyl)urea-d4;
CAS Number:1794779-79-5
Alternate CAS #
unlabelled: 94-20-2
Molecular Formula:C₁₀H₉D₄ClN₂O₃S
Appearance:White to Off-White Solid
Melting Point:126-128°C
Molecular Weight:280.76
Storage:20°C
Solubility:Chloroform (Slightly), Methanol (Very Slightly)
Category:Building Blocks; Isotopic Labeled Analogues; Pharmaceutical/API Drug Impurities/Metabolites;
Applications:Labelled Chlorpropamide, a sulfonylurea derivative. Chlorpropamide is a long acting hyopglycemic agent. Chlorpropamide is used in the treatment of diabetes metilus type 2. Chlorpropamide acts to increase the secretion of insulin and is not effective in patients who do not have pancreatic beta cell function.
References:Turner, R.C. et al.: Diabetes, 27, 241 (1978); Grinnell, E.H. et al.: Am. J. Med. Sci., 253, 312 (1967); Taylor, J.A.: Clin. Pharmacol. Therap., 13, 710 (1972);
To ensure the stability of our products, the efficient express delivery service will be used. We also guarantee that the products will be shipped in the box with layers of tapes to protect them against damage. The extremely low temperature products will be wrapped with dried ice, and the low temperature products will be delivered with ice bags. As for the products stored at room temperature, they will not be packed with ice bags or dried ice. Taskcm is committed to providing cost-effective products that facilitate drug delivery with our customers.
Email:sales@ebclink.com

Comments

No comments yet. Why don’t you start the discussion?

Leave a Reply

Your email address will not be published. Required fields are marked *